A Pilot Study of Radiation Therapy in Combination With Pembrolizumab in Patients With Metastatic Renal Cell Cancer
暂无分享,去创建一个
B. Leiby | A. Dicker | V. Bar-ad | R. Den | J. Hoffman-Censits | M. Hurwitz | W. Kelly | R. Kean | D. Hooper | M. Tuluc | S. Deshmukh | Jianqing Lin | C. Shaw | B. Lu | J. Johnson | L. Harshyne | J. Louie | A. Song | Sherin Philipose | Jennifer M. Johnson
[1] M. Atkins,et al. First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B. , 2019, Journal of Clinical Oncology.
[2] E. Wherry,et al. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours , 2018, British Journal of Cancer.
[3] D. Planchard,et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.
[4] G. Madonna,et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab , 2018, Journal of Immunotherapy for Cancer.
[5] J. Larkin,et al. Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427. , 2018 .
[6] A. Kawaguchi,et al. Correlation between lower balance of Th2 helper T-cells and expression of PD-L1/PD-1 axis genes enables prognostic prediction in patients with glioblastoma , 2018, Oncotarget.
[7] E. V. Van Allen,et al. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma , 2018, Journal of Immunotherapy for Cancer.
[8] Kaoru Tanaka,et al. Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[9] A. Dicker,et al. Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy , 2016, Journal of Hematology & Oncology.
[10] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[11] R. Weichselbaum,et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.
[12] C. Divino,et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. , 2009, Cancer research.
[13] S. Romagnani,et al. T-cell subsets (Th1 versus Th2). , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.